



DRUG QUANTITY MANAGEMENT POLICY – PER RX

- POLICY:** Oncology – Everolimus Drug Quantity Management Policy – Per Rx
- Afinitor® (everolimus tablets – Novartis, generic)
 - Afinitor® Disperz (everolimus tablets for oral suspension – Novartis, generic)
 - Torpenz™ (everolimus tablets – Upsher-Smith, generic)

REVIEW DATE: 08/05/2025

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Afinitor (generic), a kinase inhibitor, is indicated for the following uses:¹

- **Breast cancer**, treatment of advanced hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative disease in combination with exemestane, after failure of treatment with letrozole or anastrozole in postmenopausal women.
- **Neuroendocrine tumors (NET)**, treatment of progressive disease of pancreatic origin and progressive, well-differentiated, non-functional NET of gastrointestinal or lung origin that are unresectable, locally advanced, or metastatic in adults. Limitation of Use: Afinitor is not indicated for the treatment of patients with functional carcinoid tumors.

- **Renal cell carcinoma**, treatment of advanced disease after failure of treatment with sunitinib or sorafenib in adults.
- **Tuberous sclerosis complex (TSC)-associated renal angiomyolipoma**, treatment of adults not requiring immediate surgery.
- **TSC-associated subependymal giant cell astrocytoma (SEGA)**, treatment of patients ≥ 1 year of age who require therapeutic intervention but cannot be curatively resected.

Afinitor Disperz (generic), a kinase inhibitor, is indicated for the following uses:¹

- **TSC-associated SEGA**, treatment of patients ≥ 1 year of age who require therapeutic intervention but cannot be curatively resected.
- **TSC-associated partial-onset seizures**, adjunctive treatment of patients ≥ 2 years of age.

Torpenz (generic), a kinase inhibitor, is indicated for the following uses:³

- **Breast cancer**, treatment of advanced HR+, HER2-negative disease in combination with exemestane, after failure of treatment with letrozole or anastrozole in postmenopausal women.
- **TSC-associated renal angiomyolipoma**, treatment of adults not requiring immediate surgery.
- **TSC-associated SEGA**, treatment of patients ≥ 1 year of age who require therapeutic intervention but cannot be curatively resected.

Of note, Zortress® (everolimus tablets, generic) is indicated in combination with other drugs for prophylaxis of organ rejection in adults undergoing kidney or liver transplant.² The tablet strengths and dosing are different for Zortress and Afinitor/Torpenz. Zortress is not targeted in this policy.

Dosing

Table 1. Dosing for the Everolimus Products.^{1,3}

Indication	Afinitor (generic)	Torpenz (generic)	Afinitor Disperz (generic)
Hormone Receptor-Positive, HER2-Negative Breast Cancer	10 mg QD	10 mg QD	N/A
NET	10 mg QD	N/A	N/A
RCC	10 mg QD	N/A	N/A
TSC-Associated Renal Angiomyolipoma	10 mg QD	10 mg QD	N/A
TSC-Associated SEGA	4.5 mg/m ² QD. Titrate to maintain a trough of 5 ng/mL to 15 ng/mL	4.5 mg/m ² QD. Titrate to maintain a trough of 5 ng/mL to 15 ng/mL	4.5 mg/m ² QD. Titrate to maintain a trough of 5 ng/mL to 15 ng/mL
TSC-Associated Partial-Onset Seizures	N/A	N/A	5 mg/m ² QD. Titrate to maintain a trough of 5 ng/mL to 15 ng/mL

HER-2 – Human epidermal growth factor receptor-2; QD – Once daily; N/A – Not applicable; NET – Neuroendocrine tumor; RCC – Renal cell carcinoma; TSC – Tuberous sclerosis complex; SEGA – Subependymal Giant Cell Astrocytoma.

Dose interruption and/or dose reduction may be required to manage adverse events (50% of the original dose or increased dosing interval). Dose reductions ranging from one 2.5 mg, 5 mg, or 7.5 mg tablet once daily (QD) are also recommended for hepatic impairment or to manage drug-drug interactions (Table 2). The dose of Afinitor (generic), Torpenz (generic), and Afinitor Disperz (generic) should be increased in patients taking a concomitant P-gP and strong inducers of CYP3A4 (Table 3).

Table 2. Dose Modifications for Concurrent Use of Everolimus Products with a P-gP and Moderate CYP3A4 Inhibitor.^{1,3}

Indication	Dose Modification
Breast Cancer, NET*, RCC*, TSC-Associated Renal Angiomyolipoma	• Reduce dose to 2.5 mg QD • May increase dose to 5 mg QD if tolerated • Resume dose administered prior to inhibitor initiation, once the inhibitor is discontinued for 3 days
TSC-Associated SEGA and TSC-Associated Partial Onset Seizures*	• Reduce the daily dose by 50%. • Change to every other day dosing if the reduced dose is lower than the lowest available strength. • Resume the dose administered prior to inhibitor initiation, once the inhibitor is discontinued for 3 days. • Assess trough concentrations when initiating and discontinuing the inhibitor.

P-gP – P-glycoprotein; CYP – Cytochrome P450; NET – Neuroendocrine tumor; RCC – Renal cell carcinoma; * Afinitor and Afinitor Disperz only; TSC – Tuberos sclerosis complex; QD – Once daily; SEGA – Subependymal Giant Cell Astrocytoma.

Table 3. Dose Modifications for Concurrent Use of Everolimus Products with a P-gP and Strong CYP3A4 Inducer.^{1,3}

Indication	Dose Modification
Breast Cancer, NET*, RCC*, TSC-Associated Renal Angiomyolipoma	• Avoid co-administration where alternatives exist. • If co-administration cannot be avoided, double the daily dose using increments of ≤ 5 mg. Multiple increments may be required. • Resume the dose administered prior to inducer initiation, once an inducer is discontinued for 5 days.
TSC-Associated SEGA and TSC-Associated Partial Onset Seizures*	• Double the daily dose using increments using increments of ≥ 5 mg. Multiple increments may be required. • Addition of another strong CYP3A4 inducer may not require additional dosage modification. • Assess trough concentrations when initiating and discontinuing the inducer. • Resume the dose administered before starting any inducer, once all inducers are discontinued for 5 days.

P-gP – P-glycoprotein; CYP – Cytochrome P450; NET – Neuroendocrine tumor; RCC – Renal cell carcinoma; * Afinitor and Afinitor Disperz only; TSC – Tuberos sclerosis complex; SEGA – Subependymal Giant Cell Astrocytoma.

Availability

Afinitor tablets (generic) and Torpenz tablets (generic) are available in the following strengths: 2.5 mg, 5 mg, 7.5 mg, and 10 mg.^{1,3} Afinitor Disperz tablets for oral suspension (generic) are available in the following strengths: 2 mg, 3 mg, and 5 mg. Afinitor tablets (generic) and Afinitor Disperz tablets (generic) are supplied in a carton containing 28 tablets (4 blister cards of 7 tablets each).¹ Torpenz tablets (generic) are supplied in bottles of 30 tablets each.³

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote dose consolidation of Afinitor (generic), Afinitor Disperz (generic), and Torpenz (generic). If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity Per Rx	Home Delivery Maximum Quantity Per Rx
Afinitor® (everolimus tablets, generic)	2.5 mg tablet	30 tablets	90 tablets
	5 mg tablet	30 tablets	90 tablets
	7.5 mg tablet	30 tablets	90 tablets
Torpenz™ (everolimus tablets, generic)	10 mg tablet	30 tablets	90 tablets
Afinitor Disperz® (everolimus tablets for oral suspension, generic)	2 mg tablets for oral suspension	30 tablets	90 tablets
	3 mg tablets for oral suspension	30 tablets	90 tablets
	5 mg tablets for oral suspension	30 tablets	90 tablets

EXCEPTIONS TO THE QUANTITY LIMITS LISTED ABOVE ARE COVERED AS MEDICALLY NECESSARY WHEN THE FOLLOWING CRITERIA ARE MET. ANY OTHER EXCEPTION IS CONSIDERED NOT MEDICALLY NECESSARY.

CRITERIA

Everolimus 2.5 mg tablets (Afinitor, Torpenz, generic)

1. If the patient has Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA) and needs to increase their dose to maintain blood trough concentrations between 5 ng/mL and 15 ng/mL, approve one of the following (A or B):
 - A) If the patient's dose is 12.5 mg/day, approve 150 tablets per dispensing at retail or 450 tablets per dispensing at home delivery; OR
 - B) If the patient's dose is 17.5 mg/day, approve 210 tablets per dispensing at retail or 630 tablets per dispensing at home delivery.

Everolimus 5 mg tablets (Afinitor, Torpenz, generic)

1. If the patient has Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA) and needs to increase their dose to 25 mg/day to maintain blood trough concentrations between 5 ng/mL and 15 ng/mL, approve 150 tablets per dispensing at retail or 450 tablets per dispensing at home delivery.

Everolimus 7.5 mg tablets (Afinitor, Torpenz, generic)

1. If the patient is taking a strong cytochrome P450 (CYP)3A4 inducer and requires a dose of 15 mg/day, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery.

Note: Examples of CYP3A4 inducers include rifampin, carbamazepine, phenobarbital, phenytoin, rifabutin, and rifapentine.

2. If the patient has Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA) and needs to increase their dose to maintain blood trough concentrations between 5 ng/mL and 15 ng/mL, approve one of the following (A or B):
 - A) If the patient's dose is 15 mg/day, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery; OR
 - B) If the patient's dose is 22.5 mg/day, approve 90 tablets per dispensing at retail or 270 tablets per dispensing at home delivery.

Everolimus 10 mg tablets (Afinitor, Torpenz, generic)

1. If the patient is taking a strong cytochrome P450 (CYP)3A4 inducer and requires a dose of 20 mg/day, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery.

Note: Examples of CYP3A4 inducers include rifampin, carbamazepine, phenobarbital, phenytoin, rifabutin, and rifapentine.

2. If the patient has Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA), and who needs to increase their dose to maintain blood trough concentrations between 5 ng/mL and 15 ng/mL, approve one of the following (A or B):
 - A) If the patient's dose is 20 mg/day, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery; OR
 - B) If the patient's dose is 30 mg/day, approve 90 tablets per dispensing at retail or 270 tablets per dispensing at home delivery.

Everolimus 2 mg tablets for oral suspension (Afinitor Disperz, generic)

1. If the patient is taking a strong cytochrome P450 (CYP)3A4 inducer and requires a dose of 4 mg/day, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery.

Note: Examples of CYP3A4 inducers include rifampin, carbamazepine, phenobarbital, phenytoin, rifabutin, and rifapentine.

2. If the patient has Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA) or Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset Seizures, and needs to increase their dose to maintain blood trough concentrations between 5 ng/mL and 15 ng/mL, approve one of the following (A, B, C, D, or E):
 - A) If the patient's dose is 4 mg/day, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery; OR
 - B) If the patient's dose is 8 mg/day, approve 120 tablets per dispensing at retail or 360 tablets per dispensing at home delivery; OR

- C)** If the patient's dose is 14 mg/day, approve 210 tablets per dispensing at retail or 630 tablets per dispensing at home delivery; OR
- D)** If the patient's dose is 16 mg/day, approve 240 tablets per dispensing at retail or 720 tablets per dispensing at home delivery; OR
- E)** If the patient's dose is 22 mg/day, approve 330 tablets per dispensing at retail or 990 tablets per dispensing at home delivery.

Everolimus 3 mg tablets for oral suspension (Afinitor Disperz, generic)

- 1.** If the patient is taking a strong cytochrome P450 (CYP)3A4 inducer and requires a dose of 6 mg/day, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery.

Note: Examples of CYP3A4 inducers include rifampin, carbamazepine, phenobarbital, phenytoin, rifabutin, and rifapentine.

- 2.** If the patient has Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA) or Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset Seizures, and needs to increase their dose to maintain blood trough concentrations between 5 ng/mL and 15 ng/mL, approve one of the following (A, B, C, D, E, or F):

- A)** If the patient's dose is 6 mg/day, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery; OR
- B)** If the patient's dose is 9 mg/day, approve 90 tablets per dispensing at retail or 270 tablets per dispensing at home delivery; OR
- C)** If the patient's dose is 12 mg/day, approve 120 tablets per dispensing at retail or 360 tablets per dispensing at home delivery; OR
- D)** If the patient's dose is 18 mg/day, approve 180 tablets per dispensing at retail or 540 tablets per dispensing at home delivery; OR
- E)** If the patient's dose is 21 mg/day, approve 210 tablets per dispensing at retail or 630 tablets per dispensing at home delivery; OR
- F)** If the patient's dose is 24 mg/day, approve 240 tablets per dispensing at retail or 720 tablets per dispensing at home delivery.

Everolimus 5 mg tablets for oral suspension (Afinitor Disperz, generic)

- 1.** If the patient is taking a strong cytochrome P450 (CYP)3A4 inducer and requires a dose of 10 mg/day, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery.

Note: Examples of CYP3A4 inducers include rifampin, carbamazepine, phenobarbital, phenytoin, rifabutin, and rifapentine.

- 2.** If the patient has Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA) or Tuberous Sclerosis Complex (TSC)-Associated Partial-Onset Seizures, and needs to increase their dose to maintain blood trough concentrations between 5 ng/mL and 15 ng/mL, approve one of the following (A, B, C, D, or E):

- A)** If the patient's dose is 10 mg/day, approve 60 tablets per dispensing at retail or 180 tablets per dispensing at home delivery; OR
- B)** If the patient's dose is 15 mg/day, approve 90 tablets per dispensing at retail or 270 tablets per dispensing at home delivery; OR
- C)** If the patient's dose is 20 mg/day, approve 120 tablets per dispensing at retail or 360 tablets per dispensing at home delivery; OR

- D)** If the patient's dose is 25 mg/day, approve 150 tablets per dispensing at retail or 450 tablets per dispensing at home delivery; OR
- E)** If the patient's dose is 30 mg/day, approve 180 tablets per dispensing at retail or 540 tablets per dispensing at home delivery.

REFERENCES

1. Afinitor® tablets, Afinitor Disperz® tablets for oral suspension [prescribing information]. East Hanover, NJ: Novartis; February 2022.
2. Zortress® tablets [prescribing information]. East Hanover, NJ: Novartis; February 2024.
3. Torpenz™ tablets [prescribing information]. Maple Grove, MN: Upsher-Smith; March 2024.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	08/04/2023
Annual Revision	Torpenz (generic) 2.5 mg, 5 mg, 7.5 mg, and 10 mg tablets: New quantity limits of 30 tablets per dispensing and 90 tablets per dispensing were added to the policy. The same clinical overrides apply to Torpenz (generic) as apply to Afinitor (generic).	08/14/2024
Annual Revision	No criteria changes.	08/05/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.